GlassScriptPhysician profile
Patrick T Blanchfield
NPI 1942224886
$806.67
in general payments reported to CMS, 2019-2025
14 companies · $163 in 2025
The $163 reported for 2025 was more than what 76% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.35 · 2020: $17.96 · 2023: $375 · 2024: $211 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $749.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $194.83 | 2023-2025 | Stelara, Simponi, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $129.34 | 2023-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.15 | 2023-2024 | Trulance, Xifaxan, Plenvu |
| Lilly USA, LLC | $93.20 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $76.73 | 2023-2025 | Ibsrela |
| Pacira Pharmaceuticals Incorporated | $39.35 | 2019 | |
| Merck Sharp & Dohme LLC | $32.27 | 2023 | Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.82 | 2023 | Cyltezo |
| Amryt Pharma Holdings LTD | $19.65 | 2023 | Mycapssa |
| Abbvie INC. | $18.18 | 2025 | |
| Omeros Corporation | $17.96 | 2020 | |
| Qol Medical, LLC | $16.80 | 2023 | Sucraid |
| Ipsen Biopharmaceuticals, INC | $14.11 | 2024 | Bylvay |
| Intercept Pharmaceuticals, INC. | $13.28 | 2023 | Ocaliva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Blanchfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.